This site is intended for healthcare professionals
EMC Drug Feed
Drug information

TCP Sore Throat

OTC
Read time: 1 mins
Last updated: 19 Sep 2014
...
 

Summary of product characteristics


1. Name of the medicinal product

TCP Sore Throat Lozenge Buttercup Max Strength Sore Throat Lozenge


2. Qualitative and quantitative composition

Each lozenge contains hexylresorcinol 2.4mg.


3. Pharmaceutical form

Lozenge


4.1. Therapeutic indications

As an antiseptic, demulcent and local anaesthetic for the relief of sore throat and its associated pain.


4.2. Posology and method of administration

Route of administration: oral. Adults, elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 12 lozenges in 24 hours. Not to be given to children under 6 years.


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

Keep out of reach of children. If symptoms persist, consult your doctor. Not to be given to children under 6 years (warnings on the labelling).


4.5. Interaction with other medicinal products and other forms of interaction

None known.


4.6. Fertility, pregnancy and lactation

The product is not contra-indicated during pregnancy and lactation. However as with all medicines during this period, caution should be exercised.


4.7. Effects on ability to drive and use machines

None known.


4.8. Undesirable effects

None known.


4.9. Overdose

Hexylresorcinol overdosage may cause minor gastro-intestinal irritation.


5.1. Pharmacodynamic properties

Hexylresorcinol is a local anaesthetic for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated.


5.2. Pharmacokinetic properties

Pharmacokinetic considerations do not arise since the pharmacological action is local to the oropharyngeal cavity.


5.3. Preclinical safety data

No specific data.


6.1. List of excipients

Menthol Laevo Eucalyptus Oil Quinoline Yellow E104 Acid Brilliant Green BS E142 Sucrose/Liquid Glucose Solids


6.2. Incompatibilities

Hexylresorcinol is incompatible with acids and alkalis.


6.3. Shelf life

36 months.


6.4. Special precautions for storage

Do not store above 25°C. Store in the original package. Protect from humidity by keeping in a dry place.


6.5. Nature and contents of container

Blister strip of clear PVC/PVDC plastic laminate with aluminium foil in a cardboard carton Pack size: 24 lozenges


6.6. Special precautions for disposal and other handling

Not applicable


7. Marketing authorisation holder

Omega Pharma Ltd.1st Floor32 Vauxhall Bridge Road LONDON, SW1V 2SA United Kingdom


8. Marketing authorisation number(s)

PL 02855/0018


9. Date of first authorisation/renewal of the authorisation

7th March 2005


10. Date of revision of the text

5th August 2014

4.1 Therapeutic indications

As an antiseptic, demulcent and local anaesthetic for the relief of sore throat and its associated pain.

4.2 Posology and method of administration

Route of administration: oral. Adults, elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 12 lozenges in 24 hours. Not to be given to children under 6 years.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Keep out of reach of children. If symptoms persist, consult your doctor. Not to be given to children under 6 years (warnings on the labelling).

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Fertility, pregnancy and lactation

The product is not contra-indicated during pregnancy and lactation. However as with all medicines during this period, caution should be exercised.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

None known.

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).